| review article | Q7318358 |
| scholarly article | Q13442814 |
| P50 | author | Giovan G Di Costanzo | Q42510986 |
| P2093 | author name string | Raffaella Tortora | |
| P2860 | cites work | EASL-EORTC clinical practice guidelines: management of hepatocellular carcinoma | Q27860783 |
| Arterial embolisation or chemoembolisation versus symptomatic treatment in patients with unresectable hepatocellular carcinoma: a randomised controlled trial | Q29617955 | ||
| Randomized controlled trial of transarterial lipiodol chemoembolization for unresectable hepatocellular carcinoma | Q29617957 | ||
| Prognosis of hepatocellular carcinoma: the BCLC staging classification | Q29619984 | ||
| Radiofrequency ablation for hepatocellular carcinoma: 10-year outcome and prognostic factors. | Q30512830 | ||
| Hepatocellular carcinoma: long-term results of combined treatment with laser thermal ablation and transcatheter arterial chemoembolization | Q30670956 | ||
| Prospective randomized study of doxorubicin-eluting-bead embolization in the treatment of hepatocellular carcinoma: results of the PRECISION V study | Q33631372 | ||
| TACE combined with PEI versus TACE alone in the treatment of HCC: a meta-analysis | Q33633156 | ||
| Therapeutic equivalence in survival for hepatic arterial chemoembolization and yttrium 90 microsphere treatments in unresectable hepatocellular carcinoma: a two-cohort study | Q33691454 | ||
| Transarterial chemoembolization (TACE) plus sorafenib versus TACE for intermediate or advanced stage hepatocellular carcinoma: a meta-analysis | Q33778970 | ||
| Combination of repeated single-session percutaneous ethanol injection and transarterial chemoembolisation compared to repeated single-session percutaneous ethanol injection in patients with non-resectable hepatocellular carcinoma | Q33866389 | ||
| Randomised controlled trial of doxorubicin-eluting beads vs conventional chemoembolisation for hepatocellular carcinoma. | Q33918062 | ||
| Excellent outcome following down-staging of hepatocellular carcinoma prior to liver transplantation: an intention-to-treat analysis | Q34080984 | ||
| Comparison of yttrium-90 radioembolization and transcatheter arterial chemoembolization for the treatment of unresectable hepatocellular carcinoma | Q34089023 | ||
| The efficacy of TACE combined sorafenib in advanced stages hepatocellullar carcinoma | Q34312854 | ||
| A new prognostic classification for predicting survival in patients with hepatocellular carcinoma. Groupe d'Etude et de Traitement du Carcinome Hépatocellulaire | Q34504366 | ||
| Radiofrequency ablation improves prognosis compared with ethanol injection for hepatocellular carcinoma < or =4 cm. | Q34553099 | ||
| A randomized controlled trial of radiofrequency ablation with ethanol injection for small hepatocellular carcinoma. | Q34559241 | ||
| Transarterial therapy for hepatocellular carcinoma: which technique is more effective? A systematic review of cohort and randomized studies. | Q34581507 | ||
| Safety and efficacy of 90Y radiotherapy for hepatocellular carcinoma with and without portal vein thrombosis | Q34585175 | ||
| Neither multiple tumors nor portal hypertension are surgical contraindications for hepatocellular carcinoma | Q34593071 | ||
| Therapeutic options for intermediate-advanced hepatocellular carcinoma | Q34771990 | ||
| Radioembolization results in longer time-to-progression and reduced toxicity compared with chemoembolization in patients with hepatocellular carcinoma | Q35085486 | ||
| Prognostic staging system for hepatocellular carcinoma (CLIP score): its value and limitations, and a proposal for a new staging system, the Japan Integrated Staging Score (JIS score). | Q35097916 | ||
| Proposal of a new prognostic model for hepatocellular carcinoma: an analysis of 403 patients | Q35597216 | ||
| Combined TACE and PEI for palliative treatment of unresectable hepatocellular carcinoma. | Q35621307 | ||
| Transarterial chemoembolization plus sorafenib: a sequential therapeutic scheme for HCV-related intermediate-stage hepatocellular carcinoma: a randomized clinical trial. | Q35863880 | ||
| Meta-analysis of radiofrequency ablation in combination with transarterial chemoembolization for hepatocellular carcinoma | Q36975036 | ||
| Selection for resection of hepatocellular carcinoma and surgical strategy: indications for resection, evaluation of liver function, portal vein embolization, and resection | Q37072521 | ||
| Radiofrequency ablation: simultaneous application of multiple electrodes via switching creates larger, more confluent ablations than sequential application in a large animal model | Q37155966 | ||
| Outcomes of neoadjuvant transarterial chemoembolization to downstage hepatocellular carcinoma before liver transplantation | Q37303697 | ||
| Modified RECIST (mRECIST) assessment for hepatocellular carcinoma | Q37696396 | ||
| Is it time to reconsider the BCLC/AASLD therapeutic flow‐chart? | Q37795703 | ||
| Recommendations for liver transplantation for hepatocellular carcinoma: an international consensus conference report | Q37952030 | ||
| Consensus recommendations and review by an International Expert Panel on Interventions in Hepatocellular Carcinoma (EPOIHCC). | Q38075142 | ||
| Heterogeneity of patients with intermediate (BCLC B) Hepatocellular Carcinoma: proposal for a subclassification to facilitate treatment decisions | Q38080501 | ||
| Treatment of hepatocellular carcinoma combining sorafenib and transarterial locoregional therapy: state of the science | Q38096645 | ||
| Position paper of the Italian Association for the Study of the Liver (AISF): the multidisciplinary clinical approach to hepatocellular carcinoma | Q38114664 | ||
| Sorafenib alone versus sorafenib combined with transarterial chemoembolization for advanced-stage hepatocellular carcinoma: results of propensity score analyses. | Q38122306 | ||
| Chemoembolization combined with radiofrequency ablation for patients with hepatocellular carcinoma larger than 3 cm: a randomized controlled trial | Q38391223 | ||
| In intermediate stage hepatocellular carcinoma: radioembolization with yttrium 90 or chemoembolization? | Q38984450 | ||
| Response to transarterial chemoembolization as a biological selection criterion for liver transplantation in hepatocellular carcinoma | Q79854314 | ||
| Preoperative portal vein embolization for major liver resection: a meta-analysis | Q80402087 | ||
| Progression of alphafetoprotein before liver transplantation for hepatocellular carcinoma in cirrhotic patients: a critical factor | Q82491459 | ||
| Report of a national conference on liver allocation in patients with hepatocellular carcinoma in the United States | Q83150416 | ||
| Percutaneous thermal ablation of medium and large hepatocellular carcinoma: long-term outcome and prognostic factors | Q83394410 | ||
| Combination of radiofrequency ablation with transarterial chemoembolization for hepatocellular carcinoma: a meta-analysis | Q84130046 | ||
| Transarterial therapies for hepatocellular carcinoma | Q84917632 | ||
| Validation and modification of a proposed substaging system for patients with intermediate hepatocellular carcinoma | Q39149264 | ||
| Is surgery for large hepatocellular carcinoma justified? | Q39225087 | ||
| Comparative effectiveness of traditional chemoembolization with or without sorafenib for hepatocellular carcinoma | Q39375746 | ||
| Trends in utilization of transarterial treatments for hepatocellular carcinoma: results of a survey by the Italian Society of Interventional Radiology. | Q39410889 | ||
| A meta-analysis of survival rates of untreated patients in randomized clinical trials of hepatocellular carcinoma | Q39905453 | ||
| Extending the limits for curative liver resections by portal vein embolization. | Q39906868 | ||
| Efficacy of combination treatment modalities for intermediate and advanced hepatocellular carcinoma: intra-arterial therapies, sorafenib and novel small molecules. | Q40389227 | ||
| Transarterial chemoembolization in combination with local therapies for hepatocellular carcinoma: a meta-analysis | Q41761634 | ||
| Laparoscopic vs open hepatic resection for benign and malignant tumors: An updated meta-analysis | Q42681946 | ||
| The natural history of compensated cirrhosis due to hepatitis C virus: A 17-year cohort study of 214 patients | Q43000313 | ||
| Transarterial chemoembolization in combination with percutaneous ablation therapy in unresectable hepatocellular carcinoma: a meta-analysis | Q43120975 | ||
| Impact of tumour differentiation to select patients before liver transplantation for hepatocellular carcinoma. | Q43492530 | ||
| Radiofrequency thermal ablation: computer analysis of the size of the thermal injury created by overlapping ablations | Q43744545 | ||
| Combination therapy with transcatheter arterial chemoembolization and percutaneous ethanol injection compared with percutaneous ethanol injection alone for patients with small hepatocellular carcinoma: a randomized control study | Q43824320 | ||
| Factors predicting response and survival in 149 patients with unresectable hepatocellular carcinoma treated by combination cisplatin, interferon-alpha, doxorubicin and 5-fluorouracil chemotherapy | Q43924482 | ||
| Efficacy and safety of sorafenib in patients with advanced hepatocellular carcinoma: subanalyses of a phase III trial | Q44089673 | ||
| Combination of transcatheter arterial chemoembolization using cisplatin-lipiodol suspension and percutaneous ethanol injection for treatment of advanced small hepatocellular carcinoma | Q44158873 | ||
| Evaluation of transcatheter arterial embolization prior to percutaneous tumor ablation in patients with hepatocellular carcinoma: a randomized controlled trial | Q45164440 | ||
| Radiofrequency ablation plus chemoembolization versus radiofrequency ablation alone for hepatocellular carcinoma: a meta-analysis of randomized-controlled trials | Q45832995 | ||
| Reassessing selection criteria prior to liver transplantation for hepatocellular carcinoma utilizing the Scientific Registry of Transplant Recipients database | Q46129535 | ||
| Response to preoperative chemoembolization correlates with outcome after liver transplantation in patients with hepatocellular carcinoma | Q46419730 | ||
| Transcatheter arterial chemoembolization (TACE) in hepatocellular carcinoma (HCC): the role of angiogenesis and invasiveness | Q46821572 | ||
| Comparison of transcatheter arterial chemoembolization and microsphere embolization for treatment of unresectable hepatocellular carcinoma: a meta-analysis | Q47573274 | ||
| Survival after yttrium-90 resin microsphere radioembolization of hepatocellular carcinoma across Barcelona clinic liver cancer stages: a European evaluation. | Q50535030 | ||
| Assessment of hepatic reserve for indication of hepatic resection: decision tree incorporating indocyanine green test. | Q50775697 | ||
| Hepatocellular carcinoma: radio-frequency ablation of medium and large lesions. | Q51411965 | ||
| Radioembolization with yttrium-90 glass microspheres in hepatocellular carcinoma: European experience on safety and long-term survival. | Q51642133 | ||
| Indication of the extent of hepatectomy for hepatocellular carcinoma on cirrhosis by a simple algorithm based on preoperative variables. | Q51855885 | ||
| Sorafenib in combination with transarterial chemoembolization improves the survival of patients with unresectable hepatocellular carcinoma: a propensity score matching study. | Q53112763 | ||
| A prospective randomized trial of the preventive effect of pre-operative transcatheter arterial embolization against recurrence of hepatocellular carcinoma. | Q55176367 | ||
| Response rate and clinical outcome of HCC after first and repeated cTACE performed "on demand" | Q56979890 | ||
| The intermediate hepatocellular carcinoma stage: Should treatment be expanded? | Q56988249 | ||
| Liver transplantation for hepatocellular carcinoma: results of down-staging in patients initially outside the Milan selection criteria | Q56991938 | ||
| Phase III study of sorafenib after transarterial chemoembolisation in Japanese and Korean patients with unresectable hepatocellular carcinoma | Q57214428 | ||
| A new prognostic system for hepatocellular carcinoma: A retrospective study of 435 patients | Q60685449 | ||
| Hepatocellular carcinoma: treatment with a combination therapy of transcatheter arterial embolization and percutaneous ethanol injection | Q67916047 | ||
| Prognosis of primary hepatocellular carcinoma | Q70184664 | ||
| Treatment of large HCC: transcatheter arterial chemoembolization combined with percutaneous ethanol injection versus repeated transcatheter arterial chemoembolization | Q71539558 | ||
| The long term efficacy of combined transcatheter arterial embolization and percutaneous ethanol injection in the treatment of patients with large hepatocellular carcinoma and cirrhosis | Q74037360 | ||
| Selection criteria for hepatic resection in patients with large hepatocellular carcinoma larger than 10 cm in diameter | Q74142281 | ||
| Experimental study of large-volume microwave ablation in the liver | Q74557304 | ||
| Percutaneous microwave coagulation therapy for patients with small hepatocellular carcinoma: comparison with percutaneous ethanol injection therapy | Q77386995 | ||
| Large-volume tissue ablation with radio frequency by using a clustered, internally cooled electrode technique: laboratory and clinical experience in liver metastases | Q77528865 | ||
| Treatment outcomes for hepatocellular carcinoma using chemoembolization in combination with other therapies | Q79256125 | ||
| P433 | issue | 9 | |
| P921 | main subject | hepatocellular carcinoma | Q1148337 |
| P304 | page(s) | 1184-1191 | |
| P577 | publication date | 2015-05-01 | |
| P1433 | published in | World Journal of Hepatology | Q27723328 |
| P1476 | title | Intermediate hepatocellular carcinoma: How to choose the best treatment modality? | |
| P478 | volume | 7 |
| Q90287781 | Ablation for hepatocellular carcinoma: beyond the standard indications |
| Q42523379 | Evaluation of tolerability and efficacy of irreversible electroporation (IRE) in treatment of Child-Pugh B (7/8) hepatocellular carcinoma (HCC). |
| Q64087592 | Large hepatocellular carcinoma with local remnants after transarterial chemoembolization: treatment by sorafenib combined with radiofrequency ablation or sorafenib alone |
| Q91644066 | Rethinking the Role of Radiation Therapy in the Treatment of Unresectable Hepatocellular Carcinoma: A Data Driven Treatment Algorithm for Optimizing Outcomes |
| Q38635603 | Sorafenib-based combined molecule targeting in treatment of hepatocellular carcinoma |
| Q37601179 | Stereotactic Body Radiotherapy for Inoperable Liver Tumors: Results of a Single Institutional Experience |
| Q57821237 | The Ethanol Supernatant Extracts of Liushenwan Could Alleviate Nanodiethylnitrosamine-Induced Liver Cancer in Mice |
| Q38652404 | Treatment options for unresectable HCC with a focus on SIRT with Yttrium-90 resin microspheres |
Search more.